Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
SEC Form 4 filing (07/25/2025) discloses that Disc Medicine (IRON) director Kevin Bitterman executed two open-market sales through affiliated Atlas Venture funds.
- 07/23/2025: 29,837 common shares sold at a weighted-average price of $60.97.
- 07/24/2025: 13,033 common shares sold at a weighted-average price of $61.17.
Following the transactions, Bitterman’s indirect ownership via Atlas funds decreased from roughly 676,839 to 633,969 shares. He also continues to hold an additional 420,549 shares in Opportunity II and 51,000 shares in Atlas XII, keeping his total indirect stake above 1.1 million shares. Bitterman remains a board member and reports no derivative activity.
Disc Medicine, Inc. (IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand. The transaction was executed under a Rule 10b5-1 trading plan adopted on 03/10/2025, indicating it was pre-scheduled rather than discretionary. After the sale, Franchi retains 65,530 shares, a decrease of about 3% of her direct holdings, maintaining a sizable equity position that continues to align her interests with shareholders. No derivative securities acquisitions or dispositions were reported in this filing.
Disc Medicine, Inc. (Nasdaq: IRON) has filed a Form 8-K announcing the election of Nadim Ahmed to its Board of Directors, effective 14 July 2025. Ahmed will serve as a Class I director until the company’s 2027 annual meeting and thereafter until a successor is elected or he resigns. Under the company’s non-employee director compensation policy, he will receive $40,000 in annual cash fees (paid $10,000 quarterly) and a non-statutory option for 20,000 shares of common stock priced at the market close on the effective date. The option vests one-third on the first anniversary and the balance in equal monthly installments over the next two years, contingent on continued service. The filing notes no related-party transactions involving Ahmed and states he will enter into the standard director indemnification agreement. No other material financial or operational disclosures were provided.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
